Diabetes mellitus is not associated with enhanced bleeding risk in patients after percutaneous coronary intervention.

Autor:	M'Pembele, René, Metzen, Daniel, Czychy, Natalia, Zako, Saif, Mourikis, Philipp, Helten, Carolin, Trojovsky, Kajetan, Ignatov, Denis, Petzold, Tobias, Thienel, Manuela, Vornholz, Lilian, Bönner, Florian, Levkau, Bodo, Zeus, Tobias, Kelm, Malte, Dannenberg, Lisa, Polzin, Amin
Předmět:	HEMORRHAGE risk factors PATIENT aftercare PERCUTANEOUS coronary intervention SCIENTIFIC observation ACADEMIC medical centers CONFIDENCE intervals MULTIVARIATE analysis DIABETES SURGERY PATIENTS FISHER exact test REGRESSION analysis T-test (Statistics) PROBABILITY theory PROPORTIONAL hazards models
Zdroj:	Diabetic Medicine; May2021, Vol. 38 Issue 5, p1-3, 3p
Abstrakt:	The article discusses dual platelet inhibition (DAPT) has crucial after percutaneous coronary intervention (PCI), especially for patients with diabetes mellitus. Topics include additional vascular-dose rivaroxaban has been shown to reduce mortality; and variables have chosen based on literature research and clinical expertise to represent a typical post-PCI cohort.
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text